• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: Underwriters queue for Thermo Fisher debt offering

UPDATE: Underwriters queue for Thermo Fisher debt offering

April 23, 2010 By MassDevice staff

TMO logo

A brigade of bulge-bracket investment bankers are lining up to market the upcoming $750 million debt offering by Thermo Fisher Scientific Inc. (NYSE:TMO).

Proceeds from the deal, first announced earlier this week, will be used to redeem nearly $227 million in 30-year, floating rate convertible notes due in 2033, with the remaining funds tabbed to buy back approximately $515 million of debt at 6.125 percent interest and maturing in 2015. The new notes will be floated in two tranches — $450 million of notes maturing in 2015 and yielding 3.2 percent and a series of 10-year notes with a 4.7 percent coupon.

Banc of America Securities, the investment banking subsidiary of the commercial banking giant Bank of America (NYSE:BAC), will be responsible for finding buyers for about $184 million of the principal amount, or nearly one-quarter of the overall offering. Deutsche Bank Securities Inc. and J.P. Morgan Securities Inc. are set to offer notes totaling $151 million and $137 million, respectively, according to an underwriting agreement filed late April 22 with the federal Securities & Exchange Commission.

Overall, 16 investment banks will have a piece of the deal. Thermo Fisher officials said they expect to land about $741 million in net proceeds after paying underwriting fees.

According to an April 20 news release, $1,000 worth of the 2033 convertible notes can be turned into 33.84 shares of Thermo Fisher common stock. That works out to a conversion price of $29.55 per share, or nearly half Thermo Fisher’s current share price on the open market.

The notes are a holdover from the 2006 merger between Thermo Electron Corp. and Fisher Scientific International Inc. Fisher acquired the notes in August 2004 as part of its buyout of Apogent Technologies, which originally used the cash to buy back stock and pay down a term loan.

Since assuming responsibility for the issue, the Waltham, Mass.-based instruments maker has been paying a floating yield equal to the 3-month LIBOR rate, minus 125 basis points (now a near-negligible 0.18 percent, but previously climbing as high as 5.3 percent in late 2007 before the recent economic crisis prompted a sharp decline in interest rates).

The 2015 notes are another Fisher remnant, issued in June 2005 as part of efforts by the New Hampshire-based company to refinance and extend the maturities of its debt. In all, Thermo Electron took on nearly $1.8 billion of Fisher debt and will have re-worked all but about $330 million of convertible senior subordinated notes once the upcoming offering settles.

Filed Under: Business/Financial News, Diagnostics, News Well Tagged With: Thermo Fisher Scientific

More recent news

  • Neuronetics names Steven Pfanstiel chief financial officer
  • Medtronic to distribute Future Medical’s peripheral guidewires
  • AtriCure completes enrollment in stroke prevention trial
  • GT Medical raises $53M to support brain tumor treatment
  • Imperative Care, Proximie partner to develop surgical robot to treat stroke

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy